• Wrong document? Swap it for free
  • Written by students who passed
  • Immediately available after payment
  • Read online or as PDF
Sell
Where do you study
Your language
Start selling Create your account
Document preview thumbnail
Preview 4 out of 61 pages
Exam (elaborations)

Nr 603 Week 2 Part Two 2026 Final Paper Review Questions Answers Bundled Practice Collection

Document preview thumbnail
Preview 4 out of 61 pages

NR 603 WEEK 2 PART TWO 2026 FINAL PAPER REVIEW QUESTIONS ANSWERS BUNDLED PRACTICE COLLECTION

Content preview

NR 603 WEEK 2 PART TWO 2026 FINAL PAPER
REVIEW QUESTIONS ANSWERS BUNDLED
PRACTICE COLLECTION

◉ Question 7:
Caylee is a 5-year-old girl who is referred for evaluation by child
protective services. She was recently removed from her biological
family and placed in foster care, as her home environment was
reportedly unsafe due to conditions of extreme neglect. Her foster
mother reports that Caylee is very quiet and withdrawn and always
appears sad and disinterested in her surroundings; however, she
becomes very irritable when anything unexpected or unplanned
occurs. The foster mother became very concerned when it appeared
that Caylee was hallucinating. The PMHNP considers that:
Answer: A. Caylee is at high risk for suicide and precautions should
be taken
B. The hallucinations are consistent with brief psychotic disorder or
schizophrenia
C. The history and reported symptoms are typical of depressive
disorder in young children
D. This is a common situation when prepubertal children are
removed from the biological parents regardless of how dysfunctional
they are


◉ Question 2:

, Debi is a 15-year-old girl who is currently being treated for
depression. Her parents have been very proactive and involved in
her care, and Debi has achieved remission 2 months after beginning
treatment with a combination of pharmacotherapy and cognitive
behavioral therapy. While counseling Debi's parents about
important issues in management, the PMHNP advises that:
Answer: A. There is a > 50% likelihood that Debi's younger sibling
will develop depressive symptoms
B. The mean length of major depressive episode in adolescents is 4
months
C. 20 to 40% of adolescents who have major depressive disorder will
develop bipolar I within 5 years
D. Adolescent-onset depression typically need long-term
pharmacologic management to prevent relapses


◉ Agomelatine
Answer: Brand: Valdoxan
-Melatonin multimodal (Mel-MM)
-Agonist at melatonergic 1 and melatonergic 2 receptors
-Antagonist at 5HT2C receptors
-Not FDA approved: Rx for Depression, Generalized anxiety disorder
-Initial 25 mg/day at bedtime; after 2 weeks can increase to 50
mg/day at bedtime

,◉ Amitriptyline (Elavil)
Answer: Tricyclic antidepressant.


◉ Aripiprazole (Abilify)
Answer: Treatment for depression. Atypical antipsychotic.
"Dopamine stabilizer". Dopamine receptor antagonist in high
concentration and also stimulates increase of dopamine in low
concentrations. Side effects: insomnia, akathisia.


◉ Brexpiprazole (Rexulti)
Answer: Treatment for depression. Atypical antipsychotic


◉ Bupropion (Wellbutrin)
Answer: Antidepressant and smoking cessation aid, It can treat
depression and help people quit smoking. It can also prevent
depression caused by seasonal affective disorder (SAD).


◉ Citalopram (Celexa)
Answer: Antidepressant, SSRI: 20-40 mg qd.


◉ Clomipramine (Anafranil)
Answer: -Serotonin reuptake inhibitor (S-RI)
-Tricyclic antidepressant (TCA)

, -Parent drug is a potent serotonin reuptake inhibitor
Active metabolite is a potent norepinephrine/noradrenaline
reuptake inhibitor
-Increases serotonergic neurotransmission by blocking the
serotonin reuptake pump (transporter), -Desensitization of
serotonin receptors, especially serotonin 1A receptors
-Increases noradrenergic neurotransmission by blocking the
norepinephrine reuptake pump (transporter), -Desensitization of
beta adrenergic receptors
-Dopamine is inactivated by norepinephrine reuptake in the frontal
cortex
-Lacks dopamine transporters
-Increases dopamine neurotransmission in this part of the brain
**FDA Approved for Pediatrics in tx Obsessive-compulsive disorder
(OCD) (ages 10 and older)
*Off-Label for Pediatric Use: Depression, Severe and treatment-
resistant, depression, Cataplexy syndrome, Anxiety, Insomnia,
Neuropathic pain/chronic pain
-Full therapeutic benefits may take 2-8 weeks
-Dosing: in Peds/Adolescents/Adults:
100-250mg/day


◉ Cyamemazine (Tercian)
Answer: Treatment for depression.

Document information

Study
Uploaded on
August 22, 2026
Number of pages
61
Written in
2026/2027
Type
Exam (elaborations)
Contains
Questions & answers
£13.16

Wrong document? Swap it for free Within 14 days of purchase and before downloading, you can choose a different document. You can simply spend the amount again.
Written by students who passed
Immediately available after payment
Read online or as PDF

Sold
2
Followers
0
Items
1197
Last sold
2 days ago



Why students choose Stuvia

Created by fellow students, verified by reviews

Quality you can trust: written by students who passed their exams and reviewed by others who've used these revision notes.

Didn't get what you expected? Choose another document

No problem! You can straightaway pick a different document that better suits what you're after.

Pay as you like, start learning straight away

No subscription, no commitments. Pay the way you're used to via credit card and download your PDF document instantly.

Student with book image

“Bought, downloaded, and smashed it. It really can be that simple.”

Alisha Student

Working on your references?

Create accurate citations in APA, MLA and Harvard with our free citation generator.

Working on your references?

Frequently asked questions